Literature DB >> 11487041

Role of coagulation inhibitors in inflammation.

C T Esmon1.   

Abstract

It is becoming increasingly clear that coagulation augments inflammation and that anticoagulants, particularly natural anticoagulants, can limit the coagulation induced increases in the inflammatory response. The latter control mechanisms appear to involve not only the inhibition of the coagulation proteases, but interactions with the cells that either generate anti-inflammatory substances, such as prostacyclin, or limit cell activation. Recent studies have demonstrated a variety of mechanisms by which coagulation, particularly the generation of thrombin, factor Xa and the tissue factor-factor VIIa complex, can augment acute inflammatory responses. Many of these responses are due to the activation of one or more of the protease activated receptors. Activation of these receptors on endothelium can lead to the expression of adhesion molecules and platelet activating factor, thereby facilitating leukocyte activation. Therefore, anticoagulants that inhibit any of these factors would be expected to dampen the inflammatory response. The three major natural anticoagulant mechanisms seem to exert a further inhibition of these processes by impacting cellular responses. Antithrombin has been shown in vitro to increase prostacyclin responses and activated protein C has been shown to inhibit a variety of cellular responses including endotoxin induced calcium fluxes in monocytes and the nuclear translocation of NFKB, a key step in the generation of the inflammatory response. In some, but not all, in vivo models, these natural anticoagulants have been able to inhibit endotoxin/E. coli-mediated leukocyte activation and to diminish cytokine elaboration (TNF, IL-6 and IL-8). Phase III clinical studies for treatment of patients with severe sepsis have been completed for APC, which was successful (1), and for antithrombin, which was not (2). A phase III trial with tissue factor pathway inhibitor is in progress. In this review, the mechanisms by which the different natural anticoagulants are thought to function will be reviewed.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11487041

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  47 in total

Review 1.  Coagulation in sepsis.

Authors:  André Amaral; Steven M Opal; Jean-Louis Vincent
Journal:  Intensive Care Med       Date:  2004-05-18       Impact factor: 17.440

2.  Levels of plasma des-gamma-carboxy protein C and prothrombin in patients with liver diseases.

Authors:  Xiao-Fan He; Zhi-Bin Wen; Min-Juan Liu; Hui Zhang; Qun Li; Shi-Lin He
Journal:  World J Gastroenterol       Date:  2004-10-15       Impact factor: 5.742

3.  A novel targeted multi-functional fusion protein possesses inhibitory activities against bacteria, thrombin and platelet aggregation.

Authors:  Jiange Gao; Zongli Hu; Zhiping Zhao; Guanglei Liu; Yanrong Ren; Guoping Chen
Journal:  Protein J       Date:  2011-12       Impact factor: 2.371

4.  Hypercoagulability: interaction between inflammation and coagulation in familial Mediterranean fever.

Authors:  Guzide Aksu; Can Ozturk; Kaan Kavakli; Ferah Genel; Necil Kutukculer
Journal:  Clin Rheumatol       Date:  2006-05-24       Impact factor: 2.980

5.  Roles of protease-activated receptors in a mouse model of endotoxemia.

Authors:  Eric Camerer; Ivo Cornelissen; Hiroshi Kataoka; Daniel N Duong; Yao-Wu Zheng; Shaun R Coughlin
Journal:  Blood       Date:  2006-01-24       Impact factor: 22.113

6.  Plasma derived protein C in severe sepsis: report of two cases.

Authors:  A Tuttolomondo; A Pinto; D Di Raimondo; P Fernandez; G Licata
Journal:  Intern Emerg Med       Date:  2008-02-09       Impact factor: 3.397

7.  Synergistic induction of tissue factor by coagulation factor Xa and TNF: evidence for involvement of negative regulatory signaling cascades.

Authors:  Ayala Hezi-Yamit; Paul W Wong; Nga Bien-Ly; Laszlo G Komuves; K S Srinivasa Prasad; David R Phillips; Uma Sinha
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-16       Impact factor: 11.205

8.  Lactobacillus casei modulates the inflammation-coagulation interaction in a pneumococcal pneumonia experimental model.

Authors:  Cecilia Haro; Julio Villena; Hortensia Zelaya; Susana Alvarez; Graciela Agüero
Journal:  J Inflamm (Lond)       Date:  2009-10-16       Impact factor: 4.981

9.  Severe congenital protein C deficiency: the use of protein C concentrates (human) as replacement therapy for life-threatening blood-clotting complications.

Authors:  Paul N Knoebl
Journal:  Biologics       Date:  2008-06

10.  Nebulized antithrombin limits bacterial outgrowth and lung injury in Streptococcus pneumoniae pneumonia in rats.

Authors:  Jorrit J Hofstra; Alexander D Cornet; Bart F de Rooy; Alexander P Vlaar; Tom van der Poll; Marcel Levi; Sebastian Aj Zaat; Marcus J Schultz
Journal:  Crit Care       Date:  2009-09-09       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.